Effects of valproic acid and levetiracetam on viability and cell cycle regulatory genes expression in the OVCAR-3 cell line

Pharmacological Reports

Volumn 64, Issue 1, 2012, Pages 157-165

  Kwiecińska, Patrycja ^a   Taubøll, Erik ^b   Gregoraszczuk, Ewa Ł ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cytotoxicity; Gene expression; Levetiracetam; Ovarian cancer cell line OVCAR 3; Proliferation; Valproic acid

Indexed keywords

ACID PHOSPHATASE; BROXURIDINE; ETIRACETAM; LACTATE DEHYDROGENASE; TETRAZOLIUM; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ENZYME RELEASE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; OVARY CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GENE; UPREGULATION;

EID: 84862208154     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70742-9     Document Type: Article

References (35)

1. Anton E, Brandes D: Lysosomes in mice mammary tumors treated with cyclophosphamide. Distribution related to course of disease. Cancer, 1968, 21, 483-500.
2. Blaheta RA, Cinatl J Jr: Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev, 2002, 22, 492-511.
3. Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr: Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev, 2005, 25, 383-397. (Pubitemid 40946533)
4. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD: Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. NeuroOncol, 2010, 12, 917-927.
5. Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, González-Fierro A et al.: A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol, 2007, 18, 1529-1538. (Pubitemid 47365487)
6. Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G: Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab, 2005, 90, 1383-1389. (Pubitemid 40463993)
7. Cheng YC, Lin H, Huang MJ, Chow JM, Lin S, Liu HE: Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res, 2007, 31, 1403-1411. (Pubitemid 47212434)
8. Crepeau AZ, Treiman DM: Levetiracetam: a comprehensive review. Expert Rev Neurother, 2010, 10, 159-171.
9. Fortunati N, Bertino S, Costantino L, Bosco O, Vercellinatto I, Catalano MG, Boccuzzi G: Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett, 2008, 259, 156-164. (Pubitemid 350251639)
10. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M, Chen H: Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist, 2007, 12, 942-951. (Pubitemid 47359136)
11. Gu J, Lynch BA, Anderson D, Klitgaard H, Lu S, Elashoff M, Ebert U et al.: The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur J Neurosci, 2004, 19, 334-345. (Pubitemid 38177872)
12. Halaby R: Lysosomal enzyme-induced cell death in MCF7 and mammary gland cells. Breast Cancer Res, 2002, 4, EO01.
13. Hassel B, Taubøll E, Shaw R, Gjerstad L, Dingledine R: Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin. Epilepsia, 2010, 51, 1714-1720.
14. Hønsi TG, Stenersen J: Activity and localisation of the lysosomal marker enzymes acid phosphatase, N-acetyl- β-D-glucosaminidase, and β-galactosidase in the earth-worms Eisenia fetida and E. veneta. Comp Biochem Physiol B Biochem Mol Biol, 2000, 125, 429-437. (Pubitemid 30249076)
15. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CACancer J Clin, 2009, 59, 225-249.
16. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U: The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica, 2006, 91, 248-251.
17. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC: Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC.Mol Cancer Ther, 2005, 4, 1912-1922. (Pubitemid 43056974)
18. Li Y, Jenkins CW, Nichols MA, Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene, 1994, 9, 2261-2268. (Pubitemid 24228676)
19. Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW et al.: Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci, 2008, 99, 1218-1226.
20. Malumbres M, Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci, 2005, 30, 630-641. (Pubitemid 41540083)
21. Maschio M, Albani F, Baruzzi A, Zarabla A, Dinapoli L, Pace A, Pompili A et al.: Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol, 2006, 80, 97-100. (Pubitemid 44473268)
22. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M et al.: In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol, 2008, 143, 520-531.
23. Newton HB, Dalton J, Goldlust S, Pearl D: Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol 2007, 84, 293-296.
24. Newton HB, Goldlust SA, Pearl D: Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol, 2006, 78, 99-102. (Pubitemid 43786667)
25. Partap S, Fisher PG: Levetiracetam for seizures in children with brain tumors and other cancers. Pediatr Blood Cancer, 2009, 52, 288-289.
26. Paulson L, Persson A, Vonck K, Van Dycke A, Kuhn HG, Boon P, Ben-Menachem E, Raedt R: Effect of levetiracetam on hippocampal protein expression and cell proliferation in rats. Epilepsy Res, 2010, 90, 110-120.
27. Ruggiero A, Rizzo D, Mastrangelo S, Battaglia D, AttinàG, Riccardi R: Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment? Pediatr Blood Cancer, 2010, 54, 193-198.
28. Sherr CJ: Cancer cell cycles. Science, 1996, 274, 1672-1677.
29. Szaflarski JP, Meckler JM, Szaflarski M, Shutter LA, Privitera MD, Yates SL: Levetiracetam use in critically ill patients. Neurocrit Care, 2007, 7, 140-147. (Pubitemid 350242663)
30. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res, 2004, 10, 1141-1149. (Pubitemid 38198916)
31. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP: Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer, 2004, 101, 2760-2770. (Pubitemid 39603184)
32. Travaglini L, Vian L, Billi M, Grignani F, Nervi C: Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol, 2009, 41, 225-234.
33. Trollmann R, Schneider J, Keller S, Strasser K, Wenzel D, Rascher W, Ogunshola OO, Gassmann M: HIF-1-regulated vasoactive systems are differentially involved in acute hypoxic stress responses of the developing brain of newborn mice and are not affected by levetiracetam. Brain Res, 2008, 1199, 27-36.
34. Valentini A, Gravina P, Federici G, Bernardini S:Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther, 2007, 6, 185-191. (Pubitemid 46641621)
35. Wagner GL, Wilms EB, Van Donselaar CA, Vecht ChJ: Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure, 2003, 12, 585-586. (Pubitemid 37509054)